In addition, it has been reported that PD-L1 inhibitors have less effect on PD-L2 compared with PD-1 antibodies (8), and therefore are associated with a lower incidence of pneumonitis than the PD-1 antibodies are (9). Here, PDCD1LG2 is linked to pneumonitis.